EE200300507A - HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks - Google Patents

HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks

Info

Publication number
EE200300507A
EE200300507A EEP200300507A EEP200300507A EE200300507A EE 200300507 A EE200300507 A EE 200300507A EE P200300507 A EEP200300507 A EE P200300507A EE P200300507 A EEP200300507 A EE P200300507A EE 200300507 A EE200300507 A EE 200300507A
Authority
EE
Estonia
Prior art keywords
edema
invasion
protease inhibitors
cell migration
hiv protease
Prior art date
Application number
EEP200300507A
Other languages
English (en)
Inventor
Ensoli Barbara
Original Assignee
Istituto Superiore Di Sanita'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore Di Sanita' filed Critical Istituto Superiore Di Sanita'
Publication of EE200300507A publication Critical patent/EE200300507A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300507A 2001-04-18 2002-04-18 HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks EE200300507A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000210A ITRM20010210A1 (it) 2001-04-18 2001-04-18 Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt
PCT/EP2002/004303 WO2002087583A2 (en) 2001-04-18 2002-04-18 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation

Publications (1)

Publication Number Publication Date
EE200300507A true EE200300507A (et) 2004-02-16

Family

ID=11455472

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300507A EE200300507A (et) 2001-04-18 2002-04-18 HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks

Country Status (14)

Country Link
US (1) US20060088545A1 (et)
EP (1) EP1401447A2 (et)
CN (1) CN1700916A (et)
AP (1) AP2003002901A0 (et)
BG (1) BG108368A (et)
CA (1) CA2447748A1 (et)
CZ (1) CZ20033113A3 (et)
EA (1) EA006678B1 (et)
EE (1) EE200300507A (et)
HU (1) HUP0401199A2 (et)
IT (1) ITRM20010210A1 (et)
MX (1) MXPA03010380A (et)
SK (1) SK14212003A3 (et)
WO (1) WO2002087583A2 (et)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002346594A1 (en) * 2001-12-14 2003-06-30 Cedars-Sinai Medical Center Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
US7812034B2 (en) * 2003-11-04 2010-10-12 City Of Hope Method of using protease inhibitors for the treatment of liposarcomas
US20090010990A1 (en) * 2007-06-20 2009-01-08 Little Marisa A Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process
WO2011139378A1 (en) * 2010-05-06 2011-11-10 The Feinstein Institute For Medical Research Compounds and methods for treatment of systemic lupus erythematosus
WO2012088305A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
WO2000033654A1 (en) * 1998-12-04 2000-06-15 University Of Maryland Biotechnology Institute Use of protease inhibitors to modulate cellular pathways, immunity and therapies associated therewith

Also Published As

Publication number Publication date
WO2002087583B1 (en) 2003-11-20
HUP0401199A2 (hu) 2004-12-28
US20060088545A1 (en) 2006-04-27
BG108368A (bg) 2005-01-31
ITRM20010210A0 (it) 2001-04-18
EP1401447A2 (en) 2004-03-31
EA200301130A1 (ru) 2004-04-29
CA2447748A1 (en) 2002-11-07
WO2002087583A3 (en) 2002-12-19
MXPA03010380A (es) 2004-03-16
EA006678B1 (ru) 2006-02-24
AP2003002901A0 (en) 2003-12-31
WO2002087583A2 (en) 2002-11-07
CZ20033113A3 (cs) 2004-07-14
ITRM20010210A1 (it) 2002-10-18
SK14212003A3 (sk) 2004-06-08
CN1700916A (zh) 2005-11-23

Similar Documents

Publication Publication Date Title
CY2015055I1 (el) Διαλυματα και μεθοδος οφθαλμολογικης διαποτισης
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
ID30590A (id) Celana sekali pakai jenis-celana pendek
DE60031248D1 (de) Elektroaktive pore
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DE60111500D1 (de) Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff
DE60020100D1 (de) Dimerverbindungen und als inhibitoren der neuramidinase
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20033017L (no) Substituerte difenylheterosykluser til behandling av HCV-infeksjon
DE60135087D1 (de) Dipeptidnitrile als inhibitoren von cathepsin k
NO20024742D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
TR200103493T2 (tr) Metaloproteaz önleyicileri
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
DE60010531D1 (de) Strukturierung von elektroden in oled-bauelementen
BR0115102B1 (pt) Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
HK1052553A1 (zh) 膠原酶的溶液和晶格及其使用
EE200200328A (et) Multši kompositsioon ja meetod
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
AR028281A1 (es) Derivados de 2-(arilalquilamino) pirimidona y derivados de 2-(heteroaroarilalquilamino) pirimidona
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
DE60318139D1 (de) Isolator- und Anordnungskonfiguration
AR028068A1 (es) Nuevos derivados de 1,1-dioxotiocromano y su uso como inhibidores de trombina
EE200300507A (et) HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks